Post-marketing surveillance in the UK (1984).
作者信息
Lawson D H
出版信息
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
Abstract
摘要
相似文献
1
Post-marketing surveillance in the UK (1984).英国的上市后监测（1984年）。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
2
Post-marketing surveillance or drug acceptability study?上市后监测还是药物可接受性研究？
Br J Clin Pharmacol. 1987 Sep;24(3):281-2. doi: 10.1111/j.1365-2125.1987.tb03170.x.
3
Postmarketing surveillance: statistics and augury.上市后监测：统计与预测。
J Chronic Dis. 1984;37(12):949-52. doi: 10.1016/0021-9681(84)90072-9.
4
Immortality for old drugs?老药能否“不朽”？
Lancet. 1984 Jun 30;1(8392):1460-1. doi: 10.1016/s0140-6736(84)91946-9.
5
[Drug surveillance. Its present status, hopes for its future].[药物监测。其现状与未来展望]
Gastroenterol Clin Biol. 1984 Oct;8(10):702-3.
6
Post-marketing surveillance of new drugs.新药上市后监测
J R Coll Gen Pract. 1987 Aug;37(301):337-8.
7
[Forms of information supplied by regional drug monitoring centers. Assessment of the activity during 1984].[地区药品监测中心提供的信息形式。1984年活动评估]
Therapie. 1986 Sep-Oct;41(5):323-6.
8
Two UK Government proposals bearing on drug safety.
Adverse Drug React Toxicol Rev. 1997 Mar;16(1):1-7.
9
Monitoring of drugs after marketing.药品上市后监测
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
10
Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.1996年至2012年新型治疗药物的盒装警示及撤市趋势。
JAMA Intern Med. 2014 Oct;174(10):1704-5. doi: 10.1001/jamainternmed.2014.4854.
本文引用的文献
1
Double standards, scientific methods, and epidemiologic research.双重标准、科学方法与流行病学研究
N Engl J Med. 1982 Dec 23;307(26):1611-7. doi: 10.1056/NEJM198212233072604.
2
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.西咪替丁与胃癌：上市后监测研究的初步报告
Br Med J (Clin Res Ed). 1982 Nov 6;285(6351):1311-3. doi: 10.1136/bmj.285.6351.1311.
3
Postmarketing surveillance: practical experience with ketotifen.上市后监测：酮替芬的实际应用经验
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):911-4. doi: 10.1136/bmj.288.6421.911.
4
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
5
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.西咪替丁安全性的上市后监测：12个月死亡率报告。
Br Med J (Clin Res Ed). 1983 May 28;286(6379):1713-6. doi: 10.1136/bmj.286.6379.1713.
6
The role of record linkage in post-marketing drug surveillance.记录链接在上市后药品监测中的作用。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):77S-82S. doi: 10.1111/j.1365-2125.1986.tb02987.x.
7
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
8
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?监测新药的不良反应：“限制发布”还是“监测发布”？
Br Med J. 1977 Mar 12;1(6062):691-2. doi: 10.1136/bmj.1.6062.691.
9
Monitoring adverse reactions to drugs.监测药物不良反应。
Br Med J. 1977 Jan 8;1(6053):96-7. doi: 10.1136/bmj.1.6053.96.
10
Methodology of monitored release of a new preparation: buprenorphine.一种新制剂：丁丙诺啡的控释方法学。
Br Med J. 1979 Jul 21;2(6183):163-5. doi: 10.1136/bmj.2.6183.163.
Zotero 插件